Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Metal Detoxification with Ca-EDTA and DMSA with Standard of Care Therapy to Improve Outcomes in Patients with Acute Myeloid Leukemia or Myeloproliferative Neoplasm in Myeloid Blast Phase

Trial Status: active

This phase II trial tests how well giving metal detoxification with calcium disodium edetate (Ca-EDTA) and dimercaptosuccinic acid (DMSA) during standard of care therapy works to improve patient outcomes comparted to standard of care therapy alone in patients with acute myeloid leukemia or myeloproliferative neoplasm in myeloid blast phase. Ca-EDTA and DMSA are agents that form bonds with metal ions and are used to remove the toxic metals from the body. These metals are stored in the body (such as the bone marrow and blood) for long periods of time because the body does not have a way to eliminate, or get rid of, them. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the growth of cancer cells and/or improve the response to chemotherapy.